Tumor immune microenvironment-based therapies in pancreatic ductal adenocarcinoma: time to update the concept

Wenyu Luo,Ti Wen,Xiujuan Qu

DOI: https://doi.org/10.1186/s13046-023-02935-3

IF: 12.658

2024-01-02

Journal of Experimental & Clinical Cancer Research

Abstract:Abstract Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. The tumor immune microenvironment (TIME) formed by interactions among cancer cells, immune cells, cancer-associated fibroblasts (CAF), and extracellular matrix (ECM) components drives PDAC in a more immunosuppressive direction: this is a major cause of therapy resistance and poor prognosis. In recent years, research has advanced our understanding of the signaling mechanism by which TIME components interact with the tumor and the evolution of immunophenotyping. Through revolutionary technologies such as single-cell sequencing, we have gone from simply classifying PDACs as “cold” and “hot” to a more comprehensive approach of immunophenotyping that considers all the cells and matrix components. This is key to improving the clinical efficacy of PDAC treatments. In this review, we elaborate on various TIME components in PDAC, the signaling mechanisms underlying their interactions, and the latest research into PDAC immunophenotyping. A deep understanding of these network interactions will contribute to the effective combination of TIME-based therapeutic approaches, such as immune checkpoint inhibitors (ICI), adoptive cell therapy, therapies targeting myeloid cells, CAF reprogramming, and stromal normalization. By selecting the appropriate integrated therapies based on precise immunophenotyping, significant advances in the future treatment of PDAC are possible.

oncology

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is the issue of the immune microenvironment (TIME) in the treatment of pancreatic ductal adenocarcinoma (PDAC). Specifically, the article explores how to improve the clinical efficacy of PDAC by understanding the composition of the tumor immune microenvironment and its signaling mechanisms. PDAC is a highly lethal solid tumor, and its immune microenvironment causes the tumor to develop in a more immunosuppressive direction, which is the main reason for treatment resistance and poor prognosis. The article emphasizes the importance of a more comprehensive immunophenotypic classification of PDAC through revolutionary techniques such as single - cell sequencing, rather than simply classifying it as a "cold" or "hot" tumor. This in - depth understanding helps to effectively combine TIME - based treatment strategies, such as immune checkpoint inhibitors (ICI), adoptive cell therapies, therapies targeting myeloid cells, cancer - associated fibroblast (CAF) reprogramming, and stromal normalization. Through the selection of appropriate comprehensive therapies based on accurate immunophenotypes, significant progress in the treatment of PDAC is expected in the future.